Dendritic Cell-Targeting Fusion Peptide for Antigen Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine development faces challenges in delivering antigens to dendritic cells efficiently, leading to inadequate immune responses, especially when using antigens alone without adjuvants, and there is a lack of effective adjuvants that can induce sufficient immune responses.
Innovation Solution
A fusion peptide is developed, where a peptide with a specific motif sequence binds to dendritic cells, allowing efficient delivery of antigens and inducing immune responses without the need for adjuvants, by selectively binding to dendritic cells and enhancing vaccine effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Device complexity
If a peptide or protein antigen is administered alone, then the vaccine formulation is simple, but the antigen is hardly transferred to lymph nodes and dendritic cells, resulting in insufficient immune response
Solution Approach 1:
The patent uses a dendritic cell-targeting peptide as an intermediary carrier to mediate the delivery of antigen to dendritic cells. The peptide binds to specific receptors (Clec9a or Neuropilin-1) on dendritic cells, facilitating efficient antigen transfer and immune response induction without requiring complex adjuvant formulations.
Solution Approach 2:
The invention creates a composite structure by fusion of the dendritic cell-targeting peptide with the antigen protein or peptide. This fusion peptide combines the targeting capability of the peptide with the immunogenicity of the antigen, achieving both efficient delivery and immune response induction in a single molecular entity.
2Productivity
If conventional carrier peptides (WH or NW) are used to deliver antigens to dendritic cells, then antigen delivery is improved, but adjuvants must be used in combination to achieve sufficient vaccine effects
Solution Approach 1:
The patent merges the functions of antigen delivery and immune response induction into a single fusion peptide molecule. By fusing the dendritic cell-targeting peptide with the antigen, the invention eliminates the need for separate adjuvant components while maintaining high antigen delivery efficiency and achieving sufficient vaccine effects.
Solution Approach 2:
The fusion peptide performs multiple functions simultaneously: it acts as a carrier for antigen delivery to dendritic cells, serves as the antigen itself for immune recognition, and provides adjuvant-like effects to stimulate sufficient immune responses. This multi-functionality simplifies the vaccine formulation while maintaining efficacy.
3Reliability
If adjuvants are added to induce sufficient immune responses, then immune protection is improved, but the vaccine formulation becomes more complex and requires additional components
Solution Approach 1:
The invention extracts the adjuvant function from separate formulation components and integrates it into the fusion peptide structure itself. The dendritic cell-targeting capability and immune stimulation effects are inherent to the fusion peptide, eliminating the need for additional adjuvant substances while maintaining high immune protection levels.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The fusion peptide effectively delivers antigens to dendritic cells, inducing strong immune responses and providing excellent vaccine effects, even without the use of adjuvants, thereby reducing antigen doses and improving immune protection.
Implementation Method 1
the peptide (carrier peptide) is capable of delivering an antigen to dendritic cells efficiently... by selectively binding to dendritic cells
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
The purpose of the present invention is to provide a peptide that is capable of efficiently delivering an antigen to dendritic cells and improving the vaccine effects of the antigen. A peptide that has at least one motif sequence comprising the amino acid sequence of sequence listing 1, or an amino acid sequence comprising the aforementioned amino acid sequence, but in which a mutation has been induced in the amino acid residue at the first and/or second position of the amino acid sequence, is bound to an antigen protein or an antigen peptide to efficiently deliver the antigen protein or antigen peptide to dendritic cells, allowing for significantly superior vaccine effects to be exhibited.